IDH2 and astrocytoma (excluding glioblastoma): For TERTp mutation, EGFR highcopy amplification and CDKN2A homozygous deletion (recommended as upcoming diagnostic markers in the cIMPACT now update 3 [2] and in a novel grading system for IDH-mutant astrocytomas [3]) clinical sensitivity and specificity was equally 100%.